What Pharmstandard does

Pharmstandard is a Russian pharmaceutical manufacturer and commercialization platform headquartered in Dolgoprudny, Moscow Region. According to the company, it operates one of the largest domestic pharmaceutical manufacturing footprints in Russia, with consolidated capacity exceeding 1.7 billion packs of finished pharmaceutical products and over 700,000 litres of pharmaceutical substances annually across multiple GMP-certified, state-of-the-art production facilities compliant with EAEU GDP rules. Its portfolio spans over 400 pharmaceutical products across 30 dosage forms, including more than 140 medicines on Russia's Vital and Essential Drugs (VED) list, serving therapeutic areas such as diabetes, cardiovascular disease, gastroenterology, neurology, oncology, infectious diseases (tuberculosis, HIV, hepatitis, COVID), and orphan/autoimmune indications.

The company's business model rests on two reinforcing pillars: (1) proprietary manufacture and sale of branded and generic Rx/OTC pharmaceuticals to healthcare professionals, patients, and government procurement channels within Russia; and (2) a Business Development platform that provides end-to-end commercialization services to international pharmaceutical partners — including registration, pre-launch and launch support, marketing and sales, market access, distribution, patient navigation, medical services, knowledge management systems, digital healthcare management, localization (secondary packaging / FDF), serialization, and pharmacovigilance. The company maintains long-term GTM partnerships with over 15 major multinational pharmaceutical companies, including AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ferring, Roche, Gilead, Johnson, LifeScan, Merck, Novartis, Pfizer, Takeda, and Zentiva.

Its go-to-market is sales-led and enterprise-oriented, distributing through B2B pharma partnerships, direct government healthcare procurement for essential medicines, and retail pharmacy networks for OTC products, all within Russia. The company was founded in 2003 (with the corporate copyright notice referencing 2007) and previously traded on MOEX under PHST.RTS before being delisted; it reports 5,001–10,000 employees and is led by Viktor Kharitonin as Executive Director and Grigory Potapov as CEO. In June 2026 it signed an investment agreement at SPIEF-26 to construct a large-scale live vaccine production complex in the Technopolis special economic zone (Moscow region), in partnership with the Moscow city government, extending its footprint from small-molecule generics into biologics/vaccines.

Name

Pharmstandard

Legal name

JSC Pharmstandard

Website

https://pharmstd.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pharmstandard is a Russian pharmaceutical manufacturer operating one of the country's largest GMP-certified production footprints, supplying over 400 products across 30 dosage forms (140+ on the VED list) and providing end-to-end commercialization, distribution, and localization services to domestic healthcare channels and multinational pharma partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• GMP-certified production
• Vital essential drugs
• Contract pharmaceutical services

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pharmstandard generates revenue primarily through the manufacture and sale of pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) drugs. The company produces over 400 pharmaceutical products across 30 dosage forms, with over 140 medicines included in Russia's Vital and Essential Drugs List (VED).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Pharmstandard develops and manufactures a broad portfolio of over 400 pharmaceutical products across 30 dosage forms, including over 140 medicines on Russia's Vital and Essential Drugs List, spanning therapeutic areas such as diabetes, cardiovascular, oncology, infectious diseases, and autoimmune disorders. The company operates GMP-certified state-of-the-art manufacturing facilities capable of producing over 1.7 billion packs of finished dosage forms and 700,000 litres of pharmaceutical substances annually. It also provides end-to-end partnership services to multinational pharmaceutical companies covering registration, marketing & sales, market access, distribution, serialization, localization, and pharmacovigilance.

Product overview

Pharmstandard is Russia's leading pharmaceutical company operating as a single unified pharmaceutical manufacturing and commercialization platform. The portfolio consists of over 400 pharmaceutical products across 30 dosage forms, including 140+ Vital and Essential Drugs List medicines, supported by GMP-certified manufacturing capacity exceeding 1.7 billion packs and 700,000 litres of substances annually. The company provides integrated business development services encompassing registration, marketing, distribution, pharmacovigilance, and localization support for partner pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Products Portfolio
• GMP-certified Manufacturing Services
• Business Development and Partnership Services

Quantifiable outcome

• Manufacturing capacity of over 1.7 billion packs per year and over 700,000 litres of pharmaceutical substances
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

16 partnerships are on record, tiered core.

• Moscow Government (City of Moscow)coreStrategic or Co-development Partner · 15 June 2026
• AbbVie LLCcoreGTM or Marketing Partner
• Amgen LLC, Amgen (Europe) GmbHcoreGTM or Marketing Partner
• AstraZeneca Pharmaceuticals LLCcoreGTM or Marketing Partner
• Chiesi Pharmaceuticals LLCcoreGTM or Marketing Partner
• Eisai LLCcoreGTM or Marketing Partner
• Ferring PharmaceuticalscoreGTM or Marketing Partner
• F. Hoffmann-La Roche Ltd (Roche Moscow JSC)coreGTM or Marketing Partner
• Gilead Sciences Ireland UCcoreGTM or Marketing Partner
• JohnsoncoreGTM or Marketing Partner
• LifeScan Russia LLCcoreGTM or Marketing Partner
• Merck LLC, RussiacoreGTM or Marketing Partner
• Novartis Pharma LLCcoreGTM or Marketing Partner
• PFIZER INNOVATIONS LLCcoreGTM or Marketing Partner
• Takeda Pharmaceuticals LLCcoreGTM or Marketing Partner
• Zentiva Pharma LLCcoreGTM or Marketing Partner

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Stada Arzneimittel: European generics and consumer healthcare company with established CIS and Russian distribution. Comparable as a multinational generics-and-OTC player operating in the same Russian retail, hospital, and government procurement channels as Pharmstandard.
• Gedeon Richter: Hungarian-headquartered pharmaceutical company with a significant Russian footprint through Gedeon Richter-RUS. Comparable as a multinational manufacturer with established Russian manufacturing and a broad Rx portfolio overlapping Pharmstandard's therapeutic areas.
• KRKA: Slovenian-headquartered generic and specialty pharmaceutical manufacturer with strong presence in Russia and CIS. Comparable as a large-scale European generics/specialty manufacturer that competes with Pharmstandard in the Russian generics and VED market.

Direct peers

• Vertex (Verteks): Major Russian pharmaceutical manufacturer with a broad generics and Rx portfolio across multiple therapeutic areas. Directly comparable in scale, domestic manufacturing focus, and reliance on the Russian institutional and retail pharmacy channels.
• Geropharm: Russian pharmaceutical manufacturer specializing in endocrinology, neurology, and biotech products including insulins. Comparable as a domestic manufacturer with a strong VED-aligned portfolio and government procurement orientation.
• Valenta Pharm: Russian pharmaceutical company with branded Rx and OTC products across multiple therapeutic categories. Directly comparable in product mix, retail and hospital channel coverage, and the breadth-vs-depth portfolio strategy.
• BIOCAD: Russian biotech company developing and manufacturing biological products including biosimilars and innovative biologics. Comparable to Pharmstandard's biologics expansion ambitions and its push into higher-value specialty therapeutics in Russia.
• R-Pharm: One of Russia's largest domestic pharmaceutical manufacturers with a broad Rx and hospital portfolio and contract manufacturing capabilities. Directly comparable to Pharmstandard as a top-tier Russian pharma with diversified dosage forms and government procurement exposure.
• Polysan: Russian pharmaceutical manufacturer with a portfolio in cardiology, neurology, infectious diseases, and hospital injectables. Comparable as a domestic multi-therapeutic manufacturer competing in the same VED and government procurement channels.
• OTCPharm: Russian pharmaceutical company focused on OTC and consumer health products with strong retail pharmacy distribution. Comparable to Pharmstandard's OTC channel and the retail pharmacy distribution leg of its business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmstandard